Food Safety • Regulatory • Analysis
FDA REGULATORY BRIEF
July 20, 2026 | Cyclospora Outbreak Investigation
FDA Reverses Taylor Farms Cyclospora Finding, but Recall Remains
False-positive result removes the laboratory link, not the outbreak evidence
Analysis based on FDA, CDC, Taylor Fresh Foods and Reuters reporting
The Food and Drug Administration has withdrawn its only reported positive product test in the investigation of a major Cyclospora outbreak, acknowledging that a sample of Taylor Farms de Mexico iceberg lettuce produced a false-positive result. The correction is a significant development for Taylor Farms because it eliminates the strongest direct laboratory evidence against the company. It does not, however, end the investigation, cancel the recall or erase the epidemiologic and traceback evidence that led federal officials to focus on the company’s central-Mexico lettuce supply.
FDA said laboratory experts re-reviewed the sample after the agency announced on July 18 that shredded iceberg lettuce supplied by Taylor Farms had tested positive. The experts concluded that the signal did not represent true amplification and should be treated as a false positive. As of July 19, FDA said there were no confirmed positive Cyclospora results from any product samples. Taylor Fresh Foods said FDA apologized and informed the company that the earlier result was a mistake.
Why the Recall Remains
A negative or withdrawn product test does not automatically negate an outbreak finding. Foodborne-illness investigations combine several forms of evidence: interviews with patients about what they ate, statistical comparisons of ingredients, shipment records and traceback data, environmental information and laboratory testing. In this case, the non-laboratory evidence remains substantial.
CDC and FDA have linked more than 1,644 laboratory-confirmed illnesses in Indiana, Kentucky, Michigan, Ohio and West Virginia to shredded iceberg lettuce served at Taco Bell restaurants. Ninety-four people were hospitalized and no deaths were reported. In a Michigan ingredient-level analysis of 190 people who reported eating at Taco Bell, 90% said they ate iceberg lettuce. FDA’s traceback work found that lettuce supplied to restaurants visited by ill customers converged on Taylor Farms de Mexico.
Those findings explain why FDA continues to describe the product as implicated and why the agency is working with Taylor Farms to keep recalled lettuce off the market. Taylor Farms voluntarily removed all iceberg lettuce sourced from central Mexico from the U.S. market. The recall includes retail and food-service products, including certain Marketside iceberg salad and shredded-lettuce packages with best-if-used-by dates extending to Aug. 3. Taco Bell said it stopped using lettuce from the supplier nationwide. Taylor Farms has stressed that its other products, including Taylor Farms-branded products sold at retail, are not part of the recall.
Key Point
More than 1,644 confirmed illnesses across five states, ingredient-exposure data and traceback convergence keep the recall active even without a confirmed positive product sample.
What the False Positive Says About the Testing
FDA’s published method for detecting Cyclospora in fresh produce uses real-time polymerase chain reaction, or PCR, to look for and amplify genetic material from the parasite. The agency did not publicly explain the precise technical cause of this false positive, but its use of the phrase “true amplification” indicates that the re-review determined the initial molecular signal did not meet the standard for a valid detection.
Cyclospora testing is unusually difficult. The parasite may be present at very low and uneven concentrations, contamination can be limited to a small portion of a large shipment, and recovery of genetic material from leafy greens can be challenging. That means a positive result requires careful confirmation, while a negative result cannot prove that every head of lettuce or every shipment was free of contamination. The testing reversal therefore narrows the evidence but does not settle the source question by itself.
Analysis: A Reputational Win, Not Full Exoneration
For Taylor Farms, FDA’s correction is an important reputational and legal development. The company can now state accurately that no product sample has been confirmed positive. That distinction could matter in customer negotiations, insurance claims and any litigation arising from the outbreak. The company also can argue that a highly damaging government announcement was made before the laboratory result was fully validated.
But the correction is not the same as clearing Taylor Farms. Public-health agencies still have a strong circumstantial case based on illness patterns, ingredient exposure and supply-chain convergence. Unless those findings are revised, the central question is no longer whether FDA found Cyclospora in a particular sample; it is whether investigators can identify another supplier, farm, water source or distribution point that better explains the outbreak. Continued sampling and farm-level investigation will be crucial.
The episode also creates a credibility problem for FDA. Naming a company in connection with a positive test can trigger recalls, lost sales and lasting brand damage within hours. Correcting the record quickly is preferable to allowing an error to stand, but the one-day reversal will invite scrutiny of the agency’s confirmation procedures and communications practices. A useful next step would be a fuller technical explanation of how the erroneous signal was produced and what safeguards will be used before future preliminary findings are made public.
Bottom Line
The false-positive finding materially weakens the laboratory case against Taylor Farms, but it does not change the immediate consumer guidance. The recall remains active, the outbreak investigation remains open and consumers, restaurants and retailers should continue discarding the identified central-Mexico iceberg lettuce until FDA and CDC revise their recommendations. For the produce industry, the episode underscores both the value and the limitations of rapid molecular testing: it can sharpen an investigation, but it cannot replace epidemiology, traceback work and careful confirmation.
